1. Home
  2. SMTI vs SGMT Comparison

SMTI vs SGMT Comparison

Compare SMTI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sanara MedTech Inc.

SMTI

Sanara MedTech Inc.

HOLD

Current Price

$22.93

Market Cap

182.6M

Sector

Health Care

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.53

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMTI
SGMT
Founded
1982
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.6M
169.4M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
SMTI
SGMT
Price
$22.93
$6.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$34.00
$26.13
AVG Volume (30 Days)
38.8K
2.7M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$15,586,976.00
$2,000,000.00
Revenue This Year
$17.31
N/A
Revenue Next Year
$12.48
N/A
P/E Ratio
$439.80
N/A
Revenue Growth
32.47
N/A
52 Week Low
$16.05
$3.15
52 Week High
$35.70
$11.41

Technical Indicators

Market Signals
Indicator
SMTI
SGMT
Relative Strength Index (RSI) 68.50 44.06
Support Level $22.60 $6.43
Resistance Level $24.33 $7.06
Average True Range (ATR) 1.33 0.56
MACD 0.37 -0.22
Stochastic Oscillator 79.27 3.10

Price Performance

Historical Comparison
SMTI
SGMT

About SMTI Sanara MedTech Inc.

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: